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EDITORIAL
Transplant IgA nephropathy: De´ja` vu again?
The history of IgA nephropathy (IgAN) as a primary very serious consequences for the patient. Ponticelli et
kidney disease has been one of escalating importance al are to be applauded for applying strict rules to their
after an inconspicuous beginning. In 1968, Professor Jean study design. Retrospective studies are often flawed by
Berger first drew attention to the fact that a number inadequate attention to such rules, and the results that
of adults with recurrent gross hematuria had significant are published are difficult to interpret. Ponticelli et al
amounts of immunoglobulin A in their glomerular tufts were careful to avoid the introduction of bias in their
[1]. Subsequent investigations in the early 1970s were of- retrospective study and selected a control group of pa-
ten skeptical of Berger’s observations. Although the en- tients who were very appropriate [8].
tity of IgAN or “Berger’s disease,” became a legitimate Another interesting finding in this study was the obser-
diagnosis after many other pathologists confirmed Pro- vation of the level of proteinuria (1 g/day) at 6 months
fessor Berger’s original report, IgAN was still considered was an independent risk factor for graft failure. The
to be a “benign” diagnosis by most nephrologists for a association was not as strong as that seen with increase
decade following Berger’s pivotal findings. More re- of log-transformed plasma creatinine at the same time
cently, this disorder has been identified as the most com- point, but was nevertheless significant. This appears to
mon glomerular disease leading to chronic renal failure provide further evidence for the theory that proteinuria
[2]. Hence, it may be stated that Berger’s disease has per se is associated with progressive loss of function in
progressed from a novel observation to a potentially life- patients with IgAN—even when the disease recurs in a
threatening disorder in only three decades. renal transplant.
The history of recurrent IgAN in renal transplant pa- The major points made by Ponticelli et al are worth
tients has followed an almost identical sequence over the emphasizing. First, it is reasonable to consider living re-
last 25 years. Once again, it was Berger and his colleagues
lated transplants in patients with ESRD secondary to
who drew attention to the fact that IgAN can and does
IgAN. Second, ultimate graft survival is probably similarrecur in renal allografts [3]. However, most of the early
in patients receiving renal transplants for this disease asreports emphasized the benign nature of the condition
compared to other conditions. Finally, recurrence of IgANunder such circumstances [4]. The fact that many patients
is a potential cause for graft loss in patients with IgAN whowith recurrent IgAN do not have benign outcomes was
receive renal transplants. These conclusions and recom-reported by Odum et al in a small group of Australian pa-
mendations are generally in keeping with three excellenttients in 1994 [5] and then by Hartung et al at the Sixth
reviews of IgAN that have been published recently [9–11].International Symposium on IgAN in Adelaide, Austra-
The experience with recurrence of IgAN over the lastlia, [6]. Hartung et al reported the results of an Australian
15 years has shown once again that there is no substituteRegistry Survey of a large number of patients with IgAN
for time when the long-term consequences of medicaltransplanted between 1980 and 1990. Their results in 47
interventions are being examined. Ponticelli et al havepatients with recurrence of IgAN were in sharp contrast
provided an excellent example of this. Indeed, it wouldto earlier reports that had emphasized a benign course.
appear to be another case of de´ja` vu all over again!Nine of the patients described by Hartung et al had
returned to dialysis as a result of recurrence of IgAN by
Ronald Hoggthe time the survey was conducted!
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